5-Year Results of Pulsed Dose Rate Brachytherapy Applied as a Boost after Breast-Conserving Therapy in Patients at High Risk for Local Recurrence from Breast Cancer

Harms, Wolfgang; Krempien, Robert; Hensley, Frank W.; Berns, Christiane; Fritz, Péter; Wannenmacher, M

doi:10.1007/s00066-002-0977-9

Cited by 33 publications

(29 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Due to the small number of patients, our data showed no difference in the cosmetic outcome between patients treated with or without an external beam boost of 14-16 Gy. Another boost study using PDR brachytherapy as a tumor bed boost after 50 Gy EBRT showed 46% excellent, 34% good, 10% fair and 11% poor cosmetic outcome results after 5 years of follow-up [31]. In a HDR boost trial, the cosmetic outcome was even worse with 33% of the patients scoring poor/fair and 67% good/excellent.…”

Section: Discussionmentioning

confidence: 99%

Intraoperative Radiotherapy (IORT) as a Boost in Patients with Early-Stage Breast Cancer – Acute Toxicity

Kraus-Tiefenbacher¹,

Bauer

Kehrer³

et al. 2006

Oncol Res Treat

View full text Add to dashboard Cite

Background: We report on acute toxicities as well as the early cosmetic outcome of patients receiving intraoperative radiotherapy (IORT) followed by whole-breast radiotherapy (WBRT) compared to patients treated with standard WBRT alone. Patients and Methods: From 2/2002 until 2/2005, 84 breast cancer patients were treated with IORT during breast-conserving surgery (BCS) as a boost (20 Gy/50 kV X-rays) followed by WBRT. After wound healing, all IORT patients were treated with WBRT at a total dose of 46 Gy. For the purpose of comparison, 53 patients treated consecutively between 1/2003 and 12/2004 in our institution with BCS followed by WBRT at a total dose of 50-66 Gy, were analyzed. All patients had a defined followup schedule. Toxicities were prospectively documented using the CTC/EORTC Score. Cosmesis was evaluated after 6 months using a 1-4 score. Results: Treatment was well tolerated with no grade 3/4 acute toxicity. Rare adverse effects following IORT included wound healing problems (2%), erythema grade I-II (3%), palpable seroma (6%) and mastitis (2-4%). The number of patients with induration of the tumor bed was comparably low. Conclusion: IORT with the IntrabeamTM system applied as a boost during BCS, followed by 46 Gy WBRT, exerts similar acute toxicity as standard WBRT. Further follow-up is needed to assess long-term toxicity and efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Intraoperative Radiotherapy (IORT) as a Boost in Patients with Early-Stage Breast Cancer – Acute Toxicity

Kraus-Tiefenbacher¹,

Bauer

Kehrer³

et al. 2006

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Using interstitial boost techniques with HDR, the dose is between 10 and 16 Gy; in PDR or LDR technique (dose rate 40-100 cGy/h), and after incomplete resection, doses up to 20 Gy should be delivered [14]. If PDR/LDR technique is not available, the dose of 20 Gy can be given in a fractionated schedule.…”

Section: Boost Irradiation -Treatment Technique and Dosementioning

confidence: 99%

DEGRO Practical Guidelines for Radiotherapy of Breast Cancer I

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…[20][21][22][23][24][25][26][27][28][29][30][31][32] Three articles were results of the German-Austrian accelerated partial breast irradiation (APBI) Phase II study. 22,25,26 Because the most recent data published by Ott et al did not include data on toxicity, we included the other two articles in our analysis.…”

Section: 12mentioning

confidence: 99%

“…In the primary breast cancer, 22,23,[25][26][27][28]31 PDR was used as APBI or as a boost to EBRT. Interstitial tubes were used and treatment planning was performed on X-ray or CT scan.…”

Section: 12mentioning

confidence: 99%

“…In three studies, a geometric optimization was performed. 23,28,31 Pulse dose ranged from 0.6 to 1 Gy given every hour, except by Johansson et al 23 who applied a period time of 2 h. Both the German-Austrian APBI study and the study by Johansson et al 23 gave a total dose of approximately 50 Gy. After EBRT (40-50 Gy), a boost with PDR of 15-25 Gy was given.…”

Section: 12mentioning

confidence: 99%

See 1 more Smart Citation

A review of the clinical experience in pulsed dose rate brachytherapy

Balgobind

Koedooder

Zúñiga

et al. 2015

BJR

View full text Add to dashboard Cite

Pulsed dose rate (PDR) brachytherapy is a treatment modality that combines physical advantages of high dose rate (HDR) brachytherapy with the radiobiological advantages of low dose rate brachytherapy. The aim of this review was to describe the effective clinical use of PDR brachytherapy worldwide in different tumour locations. We found 66 articles reporting on clinical PDR brachytherapy including the treatment procedure and outcome. Moreover, PDR brachytherapy has been applied in almost all tumour sites for which brachytherapy is indicated and with good local control and low toxicity. The main advantage of PDR is, because of the small pulse sizes used, the ability to spare normal tissue. In certain cases, HDR resembles PDR brachytherapy by the use of multifractionated low-fraction dose.

show abstract

5-Year Results of Pulsed Dose Rate Brachytherapy Applied as a Boost after Breast-Conserving Therapy in Patients at High Risk for Local Recurrence from Breast Cancer

Abstract: PDR brachytherapy is safe, effective, and provides good cosmesis. A CLDR breast boost can be replaced by PDR brachytherapy without significant loss of therapeutic ratio.

Cited by 33 publications

References 48 publications

Intraoperative Radiotherapy (IORT) as a Boost in Patients with Early-Stage Breast Cancer – Acute Toxicity

Intraoperative Radiotherapy (IORT) as a Boost in Patients with Early-Stage Breast Cancer – Acute Toxicity

DEGRO Practical Guidelines for Radiotherapy of Breast Cancer I

A review of the clinical experience in pulsed dose rate brachytherapy

Contact Info

Product

Resources

About